Abstract-Abnormal hemodynamics play a central role in the development and perpetuation of high blood pressure. We hypothesized that hypertension therapy guided by noninvasive hemodynamics with impedance cardiography could aid primary care physicians in reducing blood pressure more effectively. Uncontrolled hypertensive patients on 1 to 3 medications were randomized by 3:2 ratio to either a standard arm or hemodynamic arm that used impedance cardiography (BioZ, CardioDynamics). Each patient completed 5 study visits with a 2-week washout period followed by 3 months of treatment. A total of 164 patients from 11 centers completed the study, 95 in the standard arm and 69 in the hemodynamic arm. At baseline and after washout, there were no differences between arms in number of medications or demographic, blood pressure, or hemodynamic characteristics. 
A pproximately 65 million people in the United States 1 and 1 billion people worldwide 2 have hypertension; it is the most common reason adults visit US physicians. 3 Hypertension is a major public health concern, because it significantly increases risk of coronary artery disease, heart failure, renal disease, and stroke. 4 In spite of major public health and medical education efforts and availability of effective antihypertensive agents, blood pressure (BP) control rates in the United States remain low, with only 31% of hypertensives and 54% of those actively treated and taking medications achieving BP Ͻ140/90 mm Hg. 5 Why is BP control such an elusive goal? The reasons are numerous and complex. However, inadequate pharmacological treatment remains the most common cause of uncontrolled BP in actively treated patients. 6 Hypertension is a hemodynamic-related disorder. BP rises as the result of increased systemic vascular resistance (SVR), cardiac output (CO), fluid volume, or a combination of these factors. 7, 8 Consequently, antihypertensive agents lower BP by reducing SVR, CO, fluid volume, or combinations thereof. 9 Previous authors hypothesized that hemodynamic information could help tailor therapy and subsequently improve BP control. 10 Invasive procedures for hemodynamic profiling are not warranted in outpatient clinics, and noninvasive procedures, such as echocardiography, are costly and operator dependent. 11 Impedance cardiography (ICG) has emerged as a reliable noninvasive method to measure hemodynamics in physician offices. In a randomized, controlled trial, ICG-guided treatment improved BP control rates in resistant hypertension treated by hypertension specialists. 12 We hypothesized that ICG-guided treatment could aid physicians in reducing BP more effectively than standard care in a population of uncontrolled hypertensive patients receiving 1 to 3 medications in a primary care setting.
Methods Eligibility
Male and female patients (age range, 18 to 75 years) were eligible if they had a diagnosis of essential hypertension and were currently on 1 to 3 antihypertensive medications with systolic BP of 140 to 179 mm Hg and/or diastolic BP of 90 to 109 mm Hg. Patients were excluded if they were on Ͼ3 antihypertensive agents; had abnormal laboratory findings; or had history of heart failure, left ventricular ejection fraction Ͻ40%, atrial fibrillation, severe valvular disease, cerebrovascular event within 3 months, severe renal disease, nephrotic syndrome, or cirrhosis. Patients in whom ICG might be subject to technical limitations were excluded (height Ͻ47 or Ͼ75 inches or weight Ͻ66 or Ͼ341 pounds, presence of activated minute-ventilation pacemaker, known hypersensitivity to sensor gel or adhesive, or skin lesion interfering with sensor placement). Patients who were enrolled and subsequently found to have not met the inclusion/exclusion criteria were terminated and excluded from analysis. Therefore, this was not an intention-to-treat analysis. The study was approved by an independent institutional review board, which adheres to the Declaration of Helsinki and US Code of Federal Regulations. These hypertensive outpatients provided written informed consent and had study procedures consistent with the protocol (no. 20021400).
Hemodynamic Evaluation Assignment
Eligible patients (Nϭ164) underwent a 2-week washout period at which time all of the antihypertensive medications were discontinued according to the manufacturer's recommendations. After screening and medication washout, each patient had 3 monthly office visits (Figure 1 ). After the 2-week washout period, patients meeting inclusion/exclusion criteria were randomized in a 3:2 ratio to the standard arm (nϭ95) or ICG-aided hemodynamic arm (nϭ69) using a central telephone service and stratified by site. All of the physicians were educated on the hemodynamic treatment strategy illustrated in Figure 2 .
Procedures
BP determinations were made in the seated position using the oscillometric technique. ICG data were collected by trained technicians at each visit in all of the patients, but ICG findings were not revealed in the standard arm to treating physicians or patients. ICG was performed with patients in the supine position, resting for 5 minutes before measurement (BioZ ICG Monitor, CardioDynamics). ICG involves the measurement of thoracic impedance through placement of 4 dual sensors, 2 on the neck and 2 on the chest. Electrical impedance changes are digitally processed to calculate CO, SVR, and thoracic fluid content (TFC). 13 CO and SVR are normalized for body size by indexing to each patient's body surface area to obtain cardiac index (CI) and SVR index (SVRI). TFC is the inverse of baseline chest impedance, and any changes in TFC are directly proportional to total fluid (intravascular and extravascular) changes. 14 TFC has different normal ranges for each gender that are displayed and printed for reference. The reproducibility of this ICG device in stable outpatients has been established, 15 and accuracy has been validated versus invasive methods in patients with various cardiovascular disorders. 16, 17 
Outcome Measures
Physician investigators were instructed that the treatment goal was to reduce systolic and diastolic BP as low as they believed would be beneficial to the patient and to achieve sustained BP Ͻ140/ 90 mm Hg. The primary study end points were reductions in systolic and diastolic BP from baseline and post-washout visit. Additional study end points were achievement of: (1) 
Interventions
After randomization, therapy was initiated in all of the patients at the post-washout visit, 2 weeks after screening. Physician investigators prescribed medications consistent with published guidelines, their usual practice patterns, and patient clinical characteristics. In the hemodynamic arm, the treating physician was also encouraged to use a hemodynamic treatment strategy to guide therapeutic decisions about pharmacological agents and dosing ( Figure 2 ).
Physicians could share ICG information with patients in the hemodynamic arm, and patients in both arms received education on the importance of medication compliance, which was reinforced with a nurse telephone call midway between each study visit. Compliance was assessed at each visit by asking patients to estimate the percentage of prescribed pills they had taken over the previous month. Patients were considered compliant with the prescribed protocol if pill count was Ͼ85% over the prior month.
Statistical Analysis
Data from case report forms were collected by study coordinators and entered into a locked database. Statistical analysis was performed with SAS statistical analysis software, version 8.2. Continuous variables are expressed as meanϮSD and categorical variables as n (%). Differences in continuous variables between treatment groups were examined by the Student t test and by ANOVA and in discrete variables using Fisher's exact tests. Subgroup analysis was performed in subjects with isolated systolic hypertension, age Ն55 years, and those receiving a thiazide diuretic. Additional evaluation of age-specific results was performed by a 2-way ANOVA for achievement of BP end points, in which treatment arm and dichotomized age (Ն55 years) were included in the model. In combination agents, each class and dosage was counted separately for analysis. Equivalency of defined daily doses for each class of medication was calculated using World Health Organization criteria. 18 Medication changes were evaluated in visits where such changes affected BP end points (visits 2 versus 1, 3 versus 2, and 4 versus 3). Medication class and dose were compared with the prior study visit, with any change in class or dose counted separately. Sample size was powered using 5 mm Hg as the detectable difference between treatment groups with a type I error of 5% and type II error of 20%. The expected heterogeneity in treatment approach for patients in the standard arm was offset by the greater number of patients randomized to the standard arm. Although this approach increased the probability that the standard arm results would reflect actual practice patterns, it required a larger sample size to power the study.
Results
Eleven primary care centers participated in the study between November 2002 and November 2004. Of 262 patients screened, 184 were randomized. A total of 164 patients (95 in the standard arm and 69 in the hemodynamic arm) completed the study and were analyzed. There were 20 early terminations, including 2 who withdrew and 18 who were randomized but were subsequently found not to have met BP enrollment criteria (BP Ͼ140/90 mm Hg at screening) and were removed as protocol violations. No reported adverse events (minor or serious) were attributable to ICG.
There were no differences in the number of antihypertensive medications, patient demographic, clinical, BP, or ICG variables at baseline or after washout (Table 1) . At baseline, there were no differences in the percentage of patients in the standard versus hemodynamic arm on 1 (42% versus 45%; PϾ0.05), 2 (48% versus 44%; PϾ0.05), or 3 (6% versus 10%; PϾ0.05) medications. Baseline medication usage in the Figure 3 demonstrates that goal BP (Ͻ140/90 mm Hg) was achieved more frequently in the hemodynamic arm (77% versus 57%; PϽ0.01), and the more aggressive BP (Ͻ130/85 mm Hg) was also achieved more often (55% versus 27%; PϽ0.0001).
Patients with isolated systolic hypertension in the hemodynamic arm (nϭ31) had greater systolic BP reductions from baseline (22Ϯ16 versus 11Ϯ17 mm Hg; PϽ0.01) and postwashout (28Ϯ16 versus 18Ϯ16 mm Hg; PϽ0.05) than those in the standard arm (nϭ46). Patients Ն55 years in the hemodynamic arm (nϭ33) had greater systolic BP reductions compared with the standard arm (nϭ51) from baseline (21Ϯ17 versus 11Ϯ20 mm Hg; PϽ0.05) and trended greater from post-washout (26Ϯ20 versus 21Ϯ19 mm Hg; PϾ0.05). Diastolic BP reductions were also greater in those Ն55 years in the hemodynamic arm from baseline (13Ϯ11 versus 4Ϯ12 mm Hg; PϽ0.001) and post-washout (16Ϯ11 versus 10Ϯ12 mm Hg; PϽ0.05). In patients Ն55 years, goal BP (Ͻ140/90 mm Hg) was achieved more frequently in the hemodynamic arm (76% versus 53%; PϽ0.05), and the more aggressive BP (Ͻ130/85 mm Hg) was also achieved more often (58% versus 27%; PϽ0.01). ANOVA also indicated that age Ն55 years had no effect on study end points (PϾ0.05).
SVRI was reduced to a greater extent in the hemodynamic arm than in the standard arm from baseline and post-washout. There were no significant differences between arms at the final visit for heart rate, CI, or TFC. However, the standard arm had a small but significant reduction in TFC from post-washout to final. 
Discussion
Our results demonstrate that ICG-guided antihypertensive treatment was more effective in reducing BP than standard therapy and empiric selection of antihypertensive medications. Patients in the 2 arms of our study were not significantly different at baseline, and each patient underwent a medication washout period to additionally equalize the 2 groups. The 57% BP control rate in the standard arm was substantial and compared favorably to BP control rates of long durations in large antihypertensive trials. 19, 20 However, the 77% BP control rate in the hemodynamic arm was even more impressive with an 8/7 mm Hg greater BP reduction from baseline and a 6/7 mm Hg greater BP reduction from post-washout. As a result, patients in the hemodynamic arm achieved goal BP of Ͻ140/90 mm Hg 35% more often (77% versus 57%) and the more aggressive level of BP control (Ͻ130/85 mm Hg) 104% more often (55 versus 27%) than those in the standard arm. The hemodynamic arm maintained superiority in 3 key subgroups: patients who were older, on thiazide diuretics, or had isolated systolic hypertension.
Why did the hemodynamic arm achieve greater reductions in BP and higher BP control rates than the standard arm? The fundamental difference between the two arms was that patient treatment in the hemodynamic arm was individualized and targeted at the hemodynamic abnormality associated with the elevated BP. This approach led to greater reductions in SVRI in the hemodynamic arm, which allowed greater decreases in both systolic and diastolic BP. The mechanistic and hemodynamically based improvement in BP was also demonstrated in patients achieving BP Ͻ130/85 mm Hg through significantly lower SVRI and higher CI in both arms. In theory, the larger drop in SVRI and BP levels in the hemodynamic arm could have occurred through use of more 
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medications, more effective medications, greater dosing intensity, more effective combination therapy, or better patient compliance. Our study allowed full discretion by the physician in choosing the agents, and a multitude of classes and doses within classes were used. The study was not powered to find small disparities in medication use, and most medication differences did not reach statistical significance.
On the other hand, some differences are worth noting. Patients in the standard arm were more likely to experience both increases and decreases in their medication doses, whereas medication class changes were not different between arms. This result might have been expected, because treatment in the standard arm followed guidelines and usual practice patterns in which a stepped approach to therapy contributes to a "trial-and-error" method of determining whether agents and doses are working. In the hemodynamic arm, the initial selection of antihypertensive medications appears to have been influenced by the hemodynamic data, because these patients were more likely to be prescribed a vasodilating agent to reduce SVRI. Additionally, the hemodynamic treatment strategy influenced medication use when SVRI was considered high, because patients in the hemodynamic arm were more likely to have received an ACEI, ARB, or CCB, as was suggested. The hemodynamic treatment strategy did not influence the prescription of ␤ blockers in the presence of high CI or in diuretic use in response to TFC changes. However, ␤-blocker use was lower or reduced in the presence of low or normal CI in the hemodynamic arm. Although the final number of antihypertensive medications given to patients in both arms of the study was similar, patients in the hemodynamic arm were more likely to be prescribed an ARB. However, when ACEI and ARB use was combined into a single category (renin-angiotensin-aldosterone system inhibitors), the hemodynamic arm only trended toward greater use at the final visit (87.0% versus 76.8%).
Thiazide diuretic use increased during the study but was lower than in some pharmacological trials and what hypertension guidelines currently suggest. However, the percentage of patients in both arms who were prescribed a thiazide diuretic at the final visit was very similar to the 35.6% usage that was reported in recent analysis of over 25 000 hypertensive patients. 21 The lower use of diuretics and ␤ blockers also follows the previously recognized physician preference for other antihypertensive agents. 22 Some might hypothesize that greater BP reductions could have been achieved in the standard arm if diuretics were used more frequently. However, when patients taking a thiazide diuretic were examined as a subgroup, the hemodynamic arm maintained its superiority. Additionally, although the higher doses of thiazide diuretics in the standard arm may have contributed to a greater drop in TFC from the post-washout visit, they did not lead to better BP control.
Our study was not intended to evaluate whether a particular antihypertensive agent was more effective at reducing BP than another. Rather, it was designed to determine whether providing hemodynamic data to the physician and patient could more effectively reduce BP. Whether hemodynamic data led to a more tailored approach to selection and monitoring of antihypertensive agents or by other factors, it resulted in greater reduction in BP and SVRI and better BP control. Physicians cannot adequately estimate hemodynamics from routine clinical examination or BP measurements, 23 because at similar levels of BP, SVR and CO can vary widely. Therefore, the addition of accurate, noninvasive, and readily obtainable hemodynamic measurements is clinically relevant.
Importantly, the current study also showed that patients in the hemodynamic arm were almost twice as likely to achieve BP control with normalization of both CI and SVRI. Improvements in vascular resistance may result in greater benefits in reducing cardiovascular risk than improvement in BP alone, 24 and differences in SVRI at the same BP may explain poorer prognosis for men versus women 25 and black versus nonblack patients. 26 Hemodynamics are also known to change with age. In older subjects, decreased arterial compliance and CI lead to increased SVRI, arterial BP, and pulse pressure. 27 In spite of the expected differences in the hemodynamics of older patients, this study demonstrated that hemodynamically driven, individualized therapy was similarly effective regardless of age or existence of isolated systolic hypertension.
The use of ICG to achieve greater BP control offers the potential for better short-term use of healthcare resources. In addition, the long-term benefits of even small levels of BP reduction are well known. A sustained BP reduction of 4/3 mm Hg is expected to reduce stroke risk 23%, coronary heart disease events 15%, heart failure 16%, and overall mortality 14%. 28 Accordingly, a recent meta-analysis of major hypertension trials reveals that an antihypertensive agent is judged favorably when it produces mean BP improvements versus placebo of only 3 or 4 mm Hg or versus another antihypertensive agent of only 1 or 2 mm Hg. 29 Previously, ICG has been used to profile hemodynamic variability across BP values 30 and to identify left ventricular dysfunction. 31 Changes in ICG parameters have demonstrated the hemodynamic effect of antihypertensive agents 32, 33 and dietary sodium. 34 ICG-guided therapy has shown benefit in a case series, 35 observational study, 36 and a randomized trial in resistant hypertensive patients. 12 In the randomized trial, ICG-guided therapy resulted in better final BP and greater BP control. Similar to our study, that study showed no differences in the number of medications between arms. In contrast to our study with lower diuretic doses and fewer medication changes in the hemodynamic arm, resistant hypertension patients receiving ICG-guided therapy had higher diuretic doses and more medication changes. The differences between the studies might be expected because of the difference in patients (severe hypertension on more medications versus milder hypertension on fewer medications) and setting (specialist versus generalist). However, in both studies, ICGguided therapy led to more effective treatment as evidenced by better BP outcomes.
The conclusions of this study may be limited to its duration of 3 months. However, in pharmacological trials, short-term reductions in BP are typically sustained over longer periods. 37 Another limitation may be in our use of patient-reported medication compliance. Without using automatic counting procedures, our goal was to educate both arms equally and to reinforce patient compliance with follow-up phone calls.
Lastly, treatment differences in the hemodynamic arm do not imply superiority of one medication over another, because the study was not designed to evaluate this question.
Perspectives
The results of this study indicate that ICG-guided antihypertensive therapy in uncontrolled hypertensive patients on 1 to 3 antihypertensive medications is more effective than standard care. This was evident by greater reductions in systolic and diastolic BP and by achieving a better level of BP control. Our study showed that, in clinical practice, inclusion of ICG hemodynamic assessment may improve BP control rates in patients who are not controlled on initial therapy.
